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TGR(mREN2)27 rats develop 
non-alcoholic fatty liver disease-
associated portal hypertension 
responsive to modulations of Janus-
kinase 2 and Mas receptor
Sabine Klein1, Carola-Ellen Kleine2, Andrea Pieper3, Michaela Granzow2, Sebastian Gautsch2, 
Mimoun Himmit2, Katharina Kahrmann2, Robert Schierwagen  1, Frank Erhard Uschner1, 
Fernando Magdaleno  2, Maria Eleni Naoum13, Glen Kristiansen4, Thomas Walther5,6, 
Michael Bader7,8,9,10,11, Tilman Sauerbruch2 & Jonel Trebicka  1,12,13,14
Prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing. Resulting fibrosis and portal 
hypertension, as a possible secondary event, may necessitate treatment. Overexpression of mouse 
renin in the transgenic rat model, TGR(mREN2)27, leads to spontaneous development of NAFLD. 
Therefore, we used TGR(mREN2)27 rats as a model of NAFLD where we hypothesized increased 
susceptibility and investigated fibrosis and portal hypertension and associated pathways. 12-week 
old TGR(mREN2)27 rats received either cholestatic (BDL) or toxic injury (CCl4 inhalation). Portal 
and systemic hemodynamic assessments were performed using microsphere technique with and 
without injection of the Janus-Kinase 2 (JAK2) inhibitor AG490 or the non-peptidic Ang(1-7) agonist, 
AVE0991. The extent of liver fibrosis was assessed in TGR(mREN2)27 and wild-type rats using 
standard techniques. Protein and mRNA levels of profibrotic, renin-angiotensin system components 
were assessed in liver and primary hepatic stellate cells (HSC) and hepatocytes. TGR(mREN2)27 rats 
developed spontaneous, but mild fibrosis and portal hypertension due to the activation of the JAK2/
Arhgef1/ROCK pathway. AG490 decreased migration of HSC and portal pressure in isolated liver 
perfusions and in vivo. Fibrosis or portal hypertension after cholestatic (BDL) or toxic injury (CCl4) 
was not aggravated in TGR(mREN2)27 rats, probably due to decreased mouse renin expression in 
hepatocytes. Interestingly, portal hypertension was even blunted in TGR(mREN2)27 rats (with or 
without additional injury) by AVE0991. TGR(mREN2)27 rats are a suitable model of spontaneous liver 
fibrosis and portal hypertension but not with increased susceptibility to liver damage. After additional 
injury, the animals can be used to evaluate novel therapeutic strategies targeting Mas.
Due to lifestyle changes, prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide1. Only 
a small percent of the NAFLD patients, especially those with hepatic steatosis, will develop more severe forms 
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of hepatic disease (fibrosis, cirrhosis). Therefore, steatosis, fibrosis and the development of portal hypertension 
are the principal parameters that indicate the necessity for treatment2,3. NAFLD is induced by various mecha-
nisms, some of which may be modulated by drugs. However, substances acting directly on fibrogenesis and portal 
hypertension are rare4. Thus, blunting the activation of hepatic stellate cells (HSC) represents an appropriate 
target5. Fibrosis and deposition of extracellular matrix (ECM)6 increases portal blood outflow resistance7. In 
addition, activated HSC are hyperresponsive to vasoconstrictors (e.g. angiotensin II), which further augments 
hepatic resistance to portal flow8,9. Finally, as development of portal hypertension is associated with morbidity 
and mortality10,11, adequate therapies are important. In view of the above-mentioned demographic changes, new 
animal models are necessary for preclinical drug testing.
TGR(mREN2)27 is such a model, comprising the overexpression of mouse renin in transgenic rats, which 
leads to spontaneous development of NAFLD12, and underlining the pathogenic role of the renin-angiotensin 
system (RAS) in liver disease11. The role of RAS in portal hypertension is ambiguous. There exist two main 
axes within RAS: the classic pathway with angiotensin-converting enzyme (ACE), angiotensin (Ang) II, 
Ang-II-type-1 receptor (AT1R) mediating vasoconstriction - and the alternative pathway, whereby ACE2, Ang1-
7, and the G-protein-coupled receptor Mas (MasR) mediate relaxation. Ang II, the agonist of the pro-fibrotic 
and pro-contractile AT1R, exerts its effects through Janus-Kinase 2 (JAK2) in HSC8,9. In the alternative RAS, 
ACE2 converts Ang II to Ang-(1-7), the agonist for MasR, inducing vasorelaxation mainly through nitric oxide 
synthase13. The alternative RAS has been also shown to exert beneficial effects in cirrhosis14–16. Interestingly, renin 
sets off the cascade for both, the classic and the alternative RAS, by mediating the generation of Ang I from angi-
otensinogen, which is further converted to Ang II by ACE, and can be further converted to Ang-(1-7) through 
the enzymatic activity of ACE2. Inhibition of renin, which is upstream of both pathways, leads to improved liver 
fibrosis and portal hypertension, suggesting a preponderance of the classic AT1R mediated pathway17–22. At the 
same time, overexpression of Ang II induces NAFLD in TGR(mREN2)27 rats12, a transgenic rat model with 
mouse renin overexpression. To date in these model fibrosis and portal hypertension has not been described. 
However, in humans, the renin concentration can be significantly increased by treatment with AT1R-blockers23,24. 
Since liver injury may be combined with renin overexpression25,26, but is absent in most animal models we used 
TGR(mREN2)27 rats as a model of renin-induced NAFLD. After inducing additional liver injury (BDL, CCl4) in 
TGR(mREN2)27 rats, we investigated whether these animals are more prone to fibrosis and portal hypertension.
Results
TGR(mREN2)27 rats develop spontaneous fibrosis and portal hypertension, but are not more 
prone to cholestatic or toxic liver damage. The extent of fibrosis was assessed in TGR(mREN2)27 and 
wild type (WT) rats, uninjured or subjected to BDL and CCl4 (Fig. 1). Healthy uninjured TGR(mREN2)27 rats 
show more positive hepatic Sirius red staining compared to respective WT rats. There was no significant differ-
ence between the extent of fibrosis in Sirius red staining in WT and TGR(mREN2)27 rats after injury (Fig. 1A, 
Suppl. Fig. 1A). Interestingly, in uninjured TGR(mREN2)27 rats, periportal fibrosis was observed when compared 
to WT rats (Fig. 1A). Levels of hydroxyproline were significantly higher in TGR(mREN2)27 rats than in WT 
rats without injury (Fig. 1B). Control TGR(mREN2)27 and WT animals showed similar collagen I A I (Col1a1) 
mRNA levels. While there was only a trend towards decreased collagen transcription in TGR(mREN2)27 rat 
livers two weeks after BDL, the difference to wildtype rats became significant after four weeks of BDL. Congruent 
to this finding, ten weeks of CCl4 intoxication, TGR(mREN2)27 rats showed less hepatic Col1a1 mRNA expres-
sion than the respective WT rats (Fig. 1C). While healthy TGR(mREN2)27 rats had more positive alpha smooth 
muscle actin (aSMA) areas, marker of activation of hepatic stellate cells, in livers compared to respective WT 
livers, the hepatic aSMA increased much less after CCl4 intoxication in TGR(mREN2)27 rats compared to CCl4 
intoxicated WT livers (Fig. 1D, Suppl. Fig. 1B). This was also confirmed by the total protein levels of aSMA (Suppl. 
Fig. 1C), but mRNA levels showed no differences between WT and TGR(mREN2)27 livers at baseline and after 
pathological stimuli (Fig. 1E). Already two weeks after BDL, hepatic platelet derived growth factor (PDGF)-beta 
receptor transcription showed a trend towards lower mRNA levels in TGR(mREN2)27 rat livers, reaching signif-
icance four weeks after BDL and in the CCl4 model (Fig. 1F).
TGR(mREN2)27 rats showed spontaneous portal hypertension, due to increased portal pressure and hepatic 
vascular resistance (Table 1). However, after four weeks of BDL injury, the degree of portal hypertension in 
TGR(mREN2)27 rats was similar to that found in WT rats, while CCl4-injury produced even less portal hyper-
tension in TGR(mREN2)27 rats due to decreased hepatic vascular resistance compared to WT rats (Table 1). 
While mean arterial pressure (MAP) was higher in CCl4 intoxicated TGR(mREN2)27 rats compared to WT rats, 
systemic vascular resistances were not significantly different (Table 1).
Expression of RAS components in TGR(mREN2)27 rats. Interestingly, hepatic angiotensinogen 
mRNA levels decreased after BDL, which was more pronounced in TGR(mREN2)27 rats (Fig. 2A). ACE and 
ACE2 mRNA increased after liver injury, but to a lesser extent in TGR(mREN2)27 rat livers than in WT liv-
ers (Fig. 2B,C). Moreover, hepatic rat renin mRNA expression was down-regulated after liver injury, with 
down-regulation most pronounced in TGR(mREN2)27 rats after four weeks of BDL. This direction of regulation 
was apposed in CCl4 TGR(mREN2)27 rat livers compared to the respective WT livers (Fig. 2D). In contrast, 
expression of hepatic transgene (mouse renin) was down-regulated in TGR(mREN2)27 rats (Fig. 2E), which was 
most likely due to the down-regulation in the hepatocytes, as shown in primary isolated hepatocytes from BDL 
TGR(mREN2)27 rats compared to control TGR(mREN2)27 rats (Fig. 2F).
AT1R-dependent pathways in TGR(mREN2)27 rats. Since TGR(mREN2)27 rats showed no major 
differences compared to WT rats in the in vivo disease models, we next analyzed HSC as the major cellular 
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contributor of liver fibrosis. Compared to WT HSC, HSC isolated from TGR(mREN2)27 showed higher aSMA 
mRNA expression without changes in collagen mRNA (Fig. 3A).
To evaluate the motility of the cells, we investigated migration using the scratch assay, in which HSC isolated 
from TGR(mREN2)27 showed higher migration capacity than WT HSC (Fig. 3B).
Figure 1. Characterization of healthy and fibrotic TGR(mREN2)27 rats. (A) Sirius red staining in livers of 
healthy and injured (BDL 2w, BDL 4w, CCl4 10w) WT and TGR(mREN2)27 rats. Scales represent 500 µm and 
200 µm. (B) Hepatic hydroxyproline content of uninjured and injured WT and TGR(mREN2)27 rats. Results 
are illustrated in µg/g liver. (C) Collagen 1a1 mRNA expression in WT and TGR(mREN2)27 livers. Expression 
of Col1a1 mRNA in WT controls is represented as a line. Results are expressed as x-fold change normalized to 
WT controls. (D) Hepatic aSMA immunoreactivity pictures to represent activated HSC. aSMA was performed 
in healthy and injured (BDL 2w, BDL 4w, CCl4 10w) WT and TGR(mREN2)27 rats. Scales represent 500 µm 
and 200 µm. (E) Hepatic aSMA mRNA expression in WT and TGR(mREN2)27 rats. The mRNA expression of 
aSMA in WT control livers is represented as a line. Results are illustrated as x-fold normalized to WT control 
data. (F) Hepatic Pdgf receptor mRNA expression in WT and TGR(mREN2)27 rats. All results are expressed 
as x-fold change and were normalized to WT control livers which is illustrated as a line. (A–F) Error bars 
are means ± s.e.m. Statistical analyzes; Mann-Whitney t-test. */**/***Indicates p < 0.05/p < 0.005/p < 0.0001. 










Mean arterial pressure 
(mmHg)
Ctr.
WT 7.11 ± 0.37 2.14 ± 0.33 50.26 ± 7.09 11.58 ± 2.74 118.94 ± 4.11
TGR(mREN2)27 11.24 ± 0.53*** 5.22 ± 1.07** 49.92 ± 11.12 4.68 ± 0.89* 113.64 ± 6.68
BDL (4 w)
WT 18.47 ± 1.43 10.33 ± 3.49 31.62 ± 9.71 1.92 ± 0.72 95.47 ± 5.64**
TGR(mREN2)27 14.20 ± 0.93* 10.50 ± 1.39 22.32 ± 6.20 2.34 ± 0.38*** 89.03 ± 5.41***
CCl4 (10w)
WT 22.56 ± 2.43 13.27 ± 2.43 20.55 ± 4.40 2.08 ± 0.68 91.00 ± 4.39
TGR(mREN2)27 17.8 ± 0.92*** 9.80 ± 2.43* 43.40 ± 8.35* 2.49 ± 0.21 109.60 ± 5.47*
Table 1. Hemodynamics in healthy and fibrotic TGR(mREN2)27 rats. */**/***p < 0.05/p < 0.005/p < 0.0001 vs. 
respective WT.
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Interestingly, the mRNA levels of ACE, AT2R and Mas suggest an elevated cellular alternative RAS pathway in 
activated HSC of TGR(mREN2)27 rats gained from livers of uninjured TGR(mREN2)27 rats (Fig. 3C).
Although most downstream pathways activated by AT1R were similarly regulated in WT and TGR(mREN2)27 
HSC, congruent to the unaltered mRNA expression of the receptor, HSC from TGR(mREN2)27 HSC showed 
significantly elevated ROCK2 expression (Fig. 3D). Interestingly, the total hepatic AT1R protein expression was 
elevated, but only on basal condition TGR(mREN2)27 rats and this difference disappeared after additional liver 
injury (Fig. 3E, Suppl. Fig. 1D). In parallel to this finding, JAK2 phosphorylation and its downstream component 
Arhgef1 were overexpressed in the control TGR(mREN2)27 rat livers when compared to WT (Fig. 3F, Suppl. 
Fig. 1C), a difference that could not be observed under liver injury conditions.
In order to test whether this up-regulation is relevant for the spontaneous portal hypertension observed in 
TGR(mREN2)27 rats (Table 1), AG490 compound was used to inhibit JAK2. Indeed, AG490 decreased portal pres-
sure and hepatic vascular resistance in TGR(mREN2)27 rats (Fig. 4A). This effect was also confirmed by in situ liver 
perfusion experiments in TGR(mREN2)27 livers, showing a dose-dependent relaxation of the intrahepatic vascular 
system (Fig. 4B). Furthermore, migration of TGR(mREN2)27 HSC was blunted by AG490 (Fig. 4C).
Role of Mas in TGR(mREN2)27 rats. Interestingly, hepatic Mas expression tended to be higher in 
TGR(mREN2)27 rats than in WT rats at mRNA and protein levels, reaching significance in CCl4 induced fibrosis 
(Fig. 5A,B, Suppl. Fig. 1D). To test whether this up-regulation of Mas is relevant in vivo, its agonist AVE0991 was 
injected in control TGR(mREN2)27 animals, as well as after four weeks of BDL and ten weeks of CCl4. A signifi-
cant decrease of portal pressure due to a drop in hepatic vascular resistance was observed in TGR(mREN2)27 rats 
in all models (Fig. 5C,D, Table 2). Secondary changes in the systemic circulation were also observed. However, in 
splanchnic vascular resistance, they were not significant (Table 2).
Interestingly, AVE0991 decreased Mas expression but led to a relative increase in ACE2 mRNA levels 
(Fig. 5E,F), which might be a feedback regulation to the reduced Mas mRNA expression in response to AVE0991. 
Notably, ACE and AT1R were not substantially influenced (Suppl. Fig. 1E,F).
Discussion
This study shows for the first time that TGR(mREN2)27 rats develop spontaneous fibrosis and portal hyperten-
sion, in addition to previously described steatosis and inflammation12. Renin-induced portal hypertension can 
be ameliorated either by JAK2 inhibitors or Mas agonists. Surprisingly, renin overexpression does not exacerbate 
cholestatic or toxic liver damage.
Figure 2. Hepatic gene expression levels of the renin-angiotensin system in healthy and cirrhotic 
TGR(mREN2)27 rats. (A) Hepatic angiotensinogen mRNA expression in control, BDL (2w, 4w) and CCl4 
(10w) intoxicated WT and TGR(mREN2)27 rats. All results were normalized to WT control data, which 
is shown as a line. Results are expressed as x-fold change. ACE mRNA expression in livers of WT and 
TGR(mREN2)27 rats. Results of uninjured and injured (BDL 2w, BDL 4w, CCl4 10w) rats are expressed as x-fold 
change to WT control data, which is illustrated as a line. mRNA levels of hepatic ACE2 expressed as x-fold level 
of transcription normalized to WT controls, shown as a line. (D) Rat renin mRNA expression in livers of WT 
and TGR(mREN2)27 rats. Results are expressed as x-fold change and normalized to WT controls, represented 
as a line. (E) Mouse renin mRNA expression in livers of uninjured TGR(mREN2)27 rats and after BDL (2w, 
4w) and CCl4 10w. Results were normalized to uninjured control TGR(mREN2)27 data and expressed as x-fold 
change. (F) Mouse renin mRNA expression in hepatocytes of control (sham) and BDL (4w) TGR(mREN2)27 
rats. Data are expressed as x-fold change of control TGR(mREN2)27 rats. Error bars are means ± s.e.m. 
Statistical analyzes; Mann-Whitney t-test. */**/***Indicates p < 0.05/p < 0.005/p < 0.0001 compared to respective 
WT data. #/##/###Indicates p < 0.05/p < 0.005/p < 0.0001 compared to TGR(mREN2)27 control data.
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Modulation of RAS might play an important role in the treatment of human NAFLD27,28, suggesting a path-
ogenic involvement of RAS in the development and progression of NAFLD. NAFLD is an emerging etiology of 
liver disease and almost 30% of the patients suffer from portal hypertension, which is associated with fibrosis in 
almost 90% of the patients2. The TGR(mREN2)27 rat model has been described to exhibit pronounced steatosis 
and inflammation already at an age of 12 weeks12 and the present study demonstrates that these animals also 
develop fibrosis and portal hypertension. This further confirms TGR(mREN2)27 as a suitable model to inves-
tigate renin-induced liver injury and portal hypertension. Moreover, TGR(mREN2)27 rats represent a NAFLD 
model of rats with mild fibrosis and significant portal hypertension regardless of any specific diet. To date, all 
NAFLD rat models necessitate an extended diet treatment and, while the animals might develop portal hyperten-
sion, they nevertheless fail to develop inflammation or fibrosis29–31. Thus, the TGR(mREN2)27 rat model possibly 
offers an advantage over the diet models in wild type rats29–31.
The concept that co-factors of liver injury may maintain portal hypertension has already been adopted by the 
Baveno VI guidelines32, and was tested in TGR(mREN2)27 rats. However, this concept could not be implemented 
in the rats in our study, since the mouse renin expression - responsible for the development of liver fibrosis and 
portal hypertension - was reduced upon cholestatic or toxic liver injury. This reduction was probably caused 
by the injury inducing loss of hepatocytes, which are the majority cell type in the liver. During liver injury the 
number of hepatocytes diminishes, and as shown by our study the gene expression of mREN is decreased in the 
hepatocytes from fibrotic animals. This reduced mouse renin expression due to injury might explain the lacking 
difference between WT and TGR(mREN2)27 rats after liver injury.
However, the TGR(mREN2)27 rats without an additional liver injury are an interesting model of liver disease 
since these animals develop NAFLD with fibrosis and portal hypertension. Indeed, classic and alternative RAS 
play an important role in different models of experimental liver cirrhosis and in different etiologies of human liver 
cirrhosis8,9,14–16. TGR(mREN2)27 rats exhibit these properties, which confirms their suitability as a model of liver 
disease. One of the pathways mediating portal hypertension in TGR(mREN2)27 rats is the overactivation of the 
JAK2-dependent pathway downstream of AT1R. Several lines of evidence confirmed this conclusion. First, the 
Figure 3. Characteristics of hepatic stellate cells in TGR(mREN2)27 rats. (A) aSMA and Col1a1 mRNA 
expression levels in TGR(mREN2)27 HSC compared to WT HSC. mRNA expression levels of WT HSC are 
represented as a line and were used for normalization of mRNA expression levels of TGR(mREN2)27 HSC. 
Results are illustrated as x-fold change. (B) Scratch assay of WT and TGR(mREN2)27 HSC to represent the 
migration after one, two and three days. Results are shown as percentage of the gap. A decreased gap represents 
an increased migration. (C) mRNA expression levels of ACE, ACE2, AT1R and Mas in HSC of TGR(mREN2)27 
rats normalized to expression levels of WT HSC, illustrated by a line. Results are shown as x-fold change. (D) 
Gene expression of Arhgef1, Jak2, RhoA and Rock2 in HSC of TGR(mREN2)27 rats compared to expression 
levels in WT HSC, which is represented as a line. Results of mRNA expression levels in TGR(mREN2)27 
HSC are normalized to WT HSC and represented as x-fold change. (E) Hepatic protein expression of AT1R 
in uninjured (control) and injured (BDL 2w, BDL 4w, CCl4 10w) TGR(mREN2)27 rats normalized and 
compared to WT livers. mRNA expressions of WT livers are represented as a line and results are illustrated 
as densitometric units. (F) Hepatic protein expression of Jak2, pJak2 and Arhgef1 in TGR(mREN2)27 rats 
(control, BDL 2w, BDL 4w, CCl4 10w). Bars are represented as percentage of densitometric units and compared 
to WT liver expression levels, shown as a line.
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transcription levels of the main components of the pathway including AT1R were increased. Further, activation 
and protein expression of JAK2 and Arhgef-1, and, finally, inhibition of JAK2 using AG490 decreased hepatic 
resistance and thereby portal pressure in these animals. Previously, we demonstrated that downstream of AT1R, 
JAK2/Arhgef1 is activated and mediated through ROCK fibrosis and portal hypertension8,9. These findings were 
independently confirmed by others33. In uninjured TGR(mREN2)27 rats, JAK2 inhibition mediated relaxation of 
hepatic stellate cells, slowed their migration and thereby decreased portal pressure in vivo via a decrease in hepatic 
vascular resistance, which was shown in vivo and in isolated liver perfusions.
Similar to human liver cirrhosis with portal hypertension, TGR(mREN2)27 rats showed elevated Mas 
expression15. AVE0991, the non-peptidic agonist of Mas, could blunt portal hypertension due to massive hepatic 
vasodilation in TGR(mREN2)27 rats, in either uninjured or cirrhotic (BDL, CCl4) models. Again, this indicates 
that Mas is an important effector of the vasculature in the presence of portal hypertension as described previously 
by others and our group14–16. The assessment of the loss-of-function of the masR would be extremely interesting 
in this setting and this is a limitation of the present work and can be further analyzed in future studies. Especially 
the hemodynamic results suggest that not only uninjured TGR(mREN2)27 rats, but also TGR(mREN2)27 rats 
after cholestatic or toxic injury are suitable for analyzing the effects of Mas. Interestingly, especially the incubation 
with AVE0991 led to a decrease of masR mRNA, significantly only in the CCl4-model. This might be due to an 
yet unknown feedback-loop, which might also explain why AVE0991 did not reduce fibrosis in the long-term 
treatment.
In summary, TGR(mREN2)27 rats develop spontaneous liver fibrosis and portal hypertension and are a suit-
able NAFLD model with mild liver fibrosis and portal hypertension. In particular after toxic or cholestatic liver 
injury, may TGR(mREN2)27 rats be used to develop novel therapeutic strategies targeting Mas.
Figure 4. Jak2 upregulation in TGR(mREN2)27 rats. (A) Portal pressure and hepatic-vascular resistance before 
and after injection of 1 mg/kg AG490. In TGR(mREN2)27 rats, portal pressure was significantly reduced after 
inhibition of Jak2 by AG490. Unit of portal pressure measurement is mmHg and of hepatic-vascular resistance 
mmHg*min*100 g/ml. (B) Perfusion pressure in situ in livers of TGR(mREN2)27 rats after precontraction with 
5 µM Ang II and after 10−6 and 10−5M AG490 in the perfusion buffer. Results are represented as percentage of 
the basal perfusion pressure. (C) Scratch assay of TGR(mREN2)27 HSC with and without AG490 treatment 
(5 µM and 25 µM) after 24 h. Migration of TGR(mREN2)27 HSC is represented as percentage of gap. Gap of 
untreated HSC are normalized to 100%. Error bars are means ± s.e.m. Statistical analyzes; Paired Wilcoxon 
signed rank test. ^/^^Indicates p < 0.05/p < 0.005 compared to measurement before AG490 treatment. 
#/###Indicates p < 0.05/p < 0.0001 compared to TGR(mREN2)27 control data.
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Figure 5. Overexpression of Mas in TGR(mREN2)27 rats. (A) Hepatic Mas mRNA expression in WT and 
TGR(mREN2)27 rats without liver injury (control) and after injury (BDL 2w, BDL 4w, CCl4 10w). mRNA 
expression data were normalized to WT control data and illustrated as x-fold change. (B) Quantification of 
hepatic Mas protein expression. Hepatic protein expression of Mas in TGR(mREN2)27 livers (control, BDL 
2w, BDL 4w, CCl4 10w) compared and normalized to WT Mas protein expression data. Results are shown as 
percentage of densitometric units and WT data were set at 100% and illustrated as a line. (C) Portal pressure 
in TGR(mREN2)27 rats. Portal pressure was measured in mmHg before and after AVE injection in control, 
BDL and CCl4 intoxicated TGR(mREN2)27 rats. (D) Hepatic-vascular resistance in TGR(mREN2)27 rats. 
Hepatic-vascular resistance was measured in control, BDL and CCl4 intoxicated TGR(mREN2)27 rats before 
and after AVE injection. Results are shown as mmHg*min*100 g/ml. (E) Hepatic Mas mRNA expression with 
and without AVE injection in TGR(mREN2)27 rats. Hepatic Mas mRNA was measured in control, BDL and 
CCl4 injected TGR(mREN2)27 rats without and with AVE injection. Data were normalized to control mRNA 
data without AVE treatment and represented as x-fold change. (F) Hepatic ACE2 mRNA expression with and 
without AVE injection in TGR(mREN2)27 rats. ACE2 mRNA expression was measured in livers of control, 
BDL and CCl4 intoxicated TGR(mREN2)27 rats with and without AVE injection. All data were normalized 
to control data without AVE injection und shown as x-fold change. Error bars are means ± s.e.m. Statistical 
analyzes; Mann-Whitney t-test. */**/***Indicates p < 0.05/p < 0.005/p < 0.0001 compared to respective WT 
data. #/###Indicates p < 0.05/p < 0.005/p < 0.0001 compared to TGR(mREN2)27 control data. Paired t-test 













before AVE0991 14.6 ± 0.93 3.84 ± 1.05 29.45 ± 4.62 128.6 ± 4.04 29.45 ± 4.62
after AVE0991 11.4 ± 0.81** 2.51 ± 0.85 24.43 ± 5.43 119.6 ± 6.12 24.43 ± 5.43
TGR(mREN2)27 BDL (4w)
before AVE0991 19.75 ± 1.70 14.94 ± 1.71 15.24 ± 1.65 75.5 ± 5.17 15.25 ± 1.65
after AVE0991 14.25 ± 1.18** 5.01 ± 1.42* 27.63 ± 13.35 74.75 ± 7.00 27.63 ± 13.35
TGR(mREN2)27 CCl4 (10w)
before AVE0991 17.8 ± 0.92 9.80 ± 2.43 43.40 ± 8.35 109.6 ± 5.47 43.40 ± 8.35
after AVE0991 9.5 ± 1.10*** 3.53 ± 0.98* 45.37 ± 8.69 126.8 ± 8.99 45.37 ± 8.69
Table 2. Hemodynamics in healthy and fibrotic TGR(mREN2)27 rats before and after AVE0991 injection. 
*/**/***p < 0.05/p < 0.005/p < 0.0001 vs. before AVE0991.
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Materials and Methods
Animals and models of liver disease. Animals. We used 79 Sprague-Dawley wild type (WT) and 90 
TGR(mREN2)27 rats. Experimental procedures were approved by the Animal Ethics Committee of Austin Health 
and of North Rhine-Westphalia (LANUV 84-02.04.2014.A137). WT and TGR(mREN2)27 rats were housed in 
a controlled environment (12 hour light/dark, temperature 22 °C to 24 °C) and fed standard rat chow ad libitum 
(Norco, Lismore NSW, Australia; Ssniff, Soest, Germany) with free access to water.
Toxic model. Eight WT and 20 TGR(mREN2)27 rats (100 g) underwent twice weekly inhalation of 1 l/min CCl4 
for ten weeks until ascites was present as described previously9,34. Age-matched control rats (ten WT and ten 
TGR(mREN2)27) did not receive CCl4.
Cholestatic model. After one week of acclimatization, BDL was performed as previously described in 40 WT and 
45 TGR(mREN2)27 rats (180 g) for four weeks9,34. BDL rats were compared to 21 WT and 15 TGR(mREN2)27 
sham-operated rats.
Hemodynamic studies. In-vivo hemodynamic studies. Once rats had developed ascites as a definite 
sign for the presence of portal hypertension, the animals were used for hemodynamic studies as described pre-
viously9,34. To assess the acute effect of AVE0991 or AG490, invasive measurements of mean arterial pressure 
(MAP) and portal pressure (PP) were performed in cirrhotic rats. AVE0991 or AG490 was administered at a dose 
of 1 mg/kg in the femoral vein.
Microsphere technique. To investigate hemodynamics, the colored microsphere technique was performed as 
described previously9,34. Before and 1 h after injection of AVE0991 or AG490, 300.000 systemic (red/white) micro-
spheres (15 µm diameter, Triton-Technologies, San Diego, USA) were injected in the left ventricle. Mesenteric 
portosystemic shunt volume was estimated before and after injection of 150.000 microspheres (yellow/blue) in 
the ileocecal vein.
In situ liver perfusion. In ten cirrhotic CCl4 intoxicated TGR(mREN2)27 rats, in situ liver perfusion was 
performed in a recirculating system as described previously9,34. After a stabilization period of 30 minutes, 
pre-contraction of the liver was induced by adding 5 µM Ang II to the Krebs-Henseleit solution. Thereafter, 
AG490 was added to the Krebs-Henseleit solution (10−6 and 10−5 M).
Hepatic hydroxyproline content. The hepatic hydroxyproline content was determined photometrically in ana-
logue segments (200 mg) of snap-frozen livers as described previously8,35.
Tissue collection. Healthy control rats and animals after induction of liver fibrosis were anesthetized and 
laparotomy was performed for tissue collection. The livers were cut into fragments and stored at −80 °C until they 
were used for qRT-PCR and Western blot analysis as described previously8,35. Segments of each liver were fixed in 
formaldehyde (4%) for paraffin embedding as described previously8,35.
Histological staining. Paraffin-embedded liver sections (2–3 µm) were treated with 0.1% Sirius red in saturated 
picric acid (Chroma, Münster, Germany) to detect collagen fibers. Hepatic Sirius red stainings were digital-
ized using Pannoramic MIDI (3DHistech, Budapest, Hungary) and quantified using Histoquant (3DHistech, 
Budapest, Hungary) as previously described8,35.
Isolation of primary hepatocytes and hepatic stellate cells. Primary rat hepatic stellate cells were 
isolated and cultured as previously described8,35. Viability and purity were routinely >95%. For early activation of 
HSCs, cells were harvested on day 10.
Cell culture. Rat hepatic stellate cells were incubated in cell culture medium (DMEM + 20% FBS + penicillin/
streptomycin) in 250 ml plastic flasks at 37 °C. After reaching 80% confluence, cells were passaged with a 1:3 split 
ratio. Detachment was achieved by incubating the cells with 0.05% Trypsin/EDTA solution (solved in PBS) for 
five minutes at 37 °C. Confluent hepatic stellate cells were incubated in media with 5 µM AG490 or with 10−5 M 
AVE0991 and harvested three days later for qRT-PCR.
Wound healing assay. Cells were cultured in cell culture medium (DMEM + 20% FBS + penicillin/streptomy-
cin) in 24-well plastic dishes at 37 °C. When cells were confluent the cell culture medium was withdrawn by 
suction and changed with the respective media. A scratch was made with a size of 1 mm. After one, two, and three 
days, the diameter of the scratch was measured and quantified using a Zeiss microscope (Primo Star, SF18). The 
results are shown as the percentage of the gap size.
qRT-PCR. Hepatic stellate cells and liver homogenates from either fibrotic or non-fibrotic rats were prepared 
using previously described methods8,35. RNA isolation, reverse transcription, and detection by real-time poly-
merase chain reaction (RT-PCR) were performed as described previously8,35. RNA was isolated from samples 
using the Qiazol reagent as instructed by the manufacturer (Qiagen, Hilden, Germany). The following assays 
provided by Applied Biosystems (Foster City, USA) were used: ACTA2 (αSMA, Rn01759928_g1), COL1A1 
(Rn00801649_g1), Tgfb1 (Rn00572010_m1), PDGFRB (Rn00709573_m1), Angiotensinogen (Rn00593114_m1), 
ACE (Rn00561094_m1), ACE2 (Rn01416293_m1), AT1R (Rn01435427_m1), Mas (Rn00562673_s1), Ccl2 
(Rn00580555_m1), Emr1 (Rn01527631_m1), Renin rat (Rn00561847_m1), Renin mouse (Mm00651435_mH), 
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Arhgef1 (Rn00572505_m1), Jak2 (Rn00676341_m1), RhoA (Rn04219609_m1) and Rock2 (Rn00564633_m1) 
(was provided by Qiagen (Hilden, Germany)). Samples were normalized to 18 s rRNA.
Western blotting. Hepatic stellate cells and liver samples were processed as previously described using 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and nitrocellulose membranes. Equal 
protein loading was assured using Ponceau-S staining. GAPDH served as endogenous control of protein expres-
sion. Membranes were incubated with rabbit-anti- Arhgef (Arhgef1), rabbit-anti-Jak2 (Jak2) from Cell Signaling 
(Danvers, MA, USA), rabbit-anti-pJak2 (pJak2, Y1007/1008), rabbit-anti-AT1R (AT1), rabbit-anti-ROCK 
(Rock2), rabbit-anti-pMoesin (p-Moesin), rabbit-anti-Mas1 (Mas) from Santa Cruz Biotechnology (Heidelberg, 
Germany) and rabbit-anti-GAPDH primary antibodies and corresponding peroxidase-coupled secondary anti-
bodies from Santa Cruz Biotechnology (Heidelberg, Germany). Results were analyzed using Chemi-Smart digital 
detection (PeqLab, Biotechnologies, Erlangen, Germany) after enhanced chemiluminescence (ECL, Amersham, 
UK).
Statistical analysis. Group size was at least n = 5 for each group. Graphs are presented as means ± stand-
ard error of the mean (SEM) and p-values < 0.05 were considered statistically significant. Western blots were 
measured using digital densitometry software (Bio-1D v.15.02, Vilber Lourmat, Marne-la-Vallée, France) and 
the respective density of each band was calculated. The fibrosis groups were tested for significance to their corre-
sponding controls using Mann-Whitney U test. In qPCR experiments, 2−ddCT was calculated and normalized to 
the respective control group. Plotting of diagrams and statistical analysis were performed using GraphPad Prism 
version 4.00 for Windows (GraphPad Software, La Jolla, California, USA).
All methods were performed in accordance with the relevant guidelines and regulations.
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